Webinar Date/Time: Tue, Jan 30, 2024 9:00 AM EST
Do you have problems with insoluble drug candidates? This new webinar highlights the use of a solubility enhancing technology that can improve performance and increase bioavailability.
Solubility remains a huge problem in the pharmaceutical industry. The Dispersome® technology is a new solubility enhancing technology and is a compelling alternative to other solubility enhancing technologies, simply because Dispersomes® provide a better performance with respect to solubility and bioavailability increase, even of practically insoluble drugs. Dispersomes® is a drug formulation technology that is based on the use of Pharma Grade Beta-lactoglobulin (BLG) as a novel pharmaceutical excipient. The Dispersome® technology stabilizes the drug into an amorphous and highly soluble form. The webinar will give a comprehensive overview on the recent developments with the Dispersome® technology. These cover the scientific insights gained, the status on the novel excipient BLG, as well as case studies for several programs.
Key Learning Objectives:
Who Should Attend:
Korbinian Löbmann, PhD
CSO and Co-Founder
Zerion Pharma A/S
Dr Korbinian Löbmann is CSO and co-founder of Zerion Pharma A/S, which was established in January 2019 in Copenhagen, Denmark. He is author of more than 120 peer reviewed publications and patents. Prior to his role in Zerion Pharma, Dr. Korbinian Löbmann had an appointment as Assoc. Prof. with a research focus on solid state pharmacteutics at the University of Copenhagen, Denmark. He received his PhD degree from the School of Pharmacy, University of Otago, Dunedin, New Zealand in 2013.